Latest News
& Announcements
We are thrilled to announce that Detact Diagnostics has earned its ISO 13485 certification.
With this achievement, we comply with the international Quality Management system standards in the medical devices industry. This significant milestone is a result of the hard work of our entire team, and we couldn't have done this without the help of our appreciated QA consultant, Annemarie Booijenga.
Detact Diagnostics becomes a member of ARMI
We are delighted to share that we have become a proud member of the Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA in Manchester, NH!
This is a significant milestone for us, as it grants us access to a vibrant community of experts, cutting-edge research, and top-notch facilities dedicated to advancing regenerative medicine and biomanufacturing.
Being part of ARMI means that we can collaborate with industry leaders, exchange ideas, and stay at the forefront of innovation in regenerative medicine. We are thrilled about the possibilities and resources this membership brings to our business, allowing us to push boundaries and explore new horizons.
Stay tuned for more updates as we embark on this incredible adventure! đź’Ş
Detact Diagnostics supports the Bill & Melinda Gates Foundation
We are delighted to announce a collaboration with the Bill & Melinda Gates Foundation to explore the technical feasibility of rapid point-of-care tests that detect either tuberculosis (TB) or active syphilis infection using our VIPER® Platform Technology. The project aims to help low- and middle-income countries (LMICs).Â
Â
Â
Preliminary tests from the lab have shown very encouraging results!Â
M2D2 Accelerator Programme
Life Science Innovation Award 2022 WINNERS!!
We are honoured and delighted to be awarded the first 'Life Science Innovation Award 2022' winners at the Life Science Conference organized by LifeCooperative.
Â
During this event, our CTO Matt Burton pitched our innovative VIPER technology and how we plan to make a huge impact in the healthcare industry.Â
Detact receives European Regional Development Fund grant upon joining the Open Diagnostics Ecosystem
In this project, Detact wants to develop technology to help doctors/healthcare providers make a diagnosis. Diagnostic tests are being designed to detect bacteria (such as "Gram-negative" bacteria Pseudomonas aeruginosa and "Gram-positive" bacteria Staphylococcus aureus) in both synovial fluid and peritoneal fluid. In addition, Detact will develop a handheld spectrometer for point-of-care detection, which will be smartphone-compatible and can be added to an electronic patient file.
Detact supported by EU & regional support towards innovation
European Regional Development Fund (ERDF) has allocated funds to the region of the Northern Netherlands, consisting of the provinces of Friesland, Groningen and Drenthe. These funds, in combination with additional public and private co-financing, will strengthen the region’s potential for research and innovation.Â
Â
SNN supports the development of our innovative technology with project subsidies for the development of the Milk-protease test and a quick E.coli test.
SNN Subsidie project publications
Click link to download (in dutch)
This programme will undoubtedly accelerate the development of our VIPER® technology and expand our horizons with access to industry leaders and like-minded companies and individuals.Â